{"id":872700,"date":"2025-08-07T09:04:31","date_gmt":"2025-08-07T13:04:31","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-receives-1-million-to-accelerate-ai-driven-drug-discovery-remains-well-capitalized-to-execute-growth-strategy\/"},"modified":"2025-08-07T09:04:31","modified_gmt":"2025-08-07T13:04:31","slug":"tevogen-receives-1-million-to-accelerate-ai-driven-drug-discovery-remains-well-capitalized-to-execute-growth-strategy","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-receives-1-million-to-accelerate-ai-driven-drug-discovery-remains-well-capitalized-to-execute-growth-strategy\/","title":{"rendered":"Tevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">\n          <strong>Funds will support advancement of Tevogen.AI, the Company\u2019s artificial intelligence\u2013driven drug discovery initiative.<\/strong>\n        <\/li>\n<li style=\"margin-bottom:8pt\">\n          <strong>The $1 million is part of up to $10 million in previously announced non-dilutive grant funding from KRHP LLC. <\/strong>\n        <\/li>\n<li style=\"margin-bottom:8pt\">\n          <strong>The Company remains well-capitalized, enabling it to fully execute its growth strategy.<\/strong><\/p>\n<\/li>\n<\/ul>\n<p>WARREN, N.J., Aug.  07, 2025  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0GnfUDTscEoHBqVKtw90k6UB5csqfhP7RyY9YGa-Uf-ztrSVuOdNzQOPsyegfdYa3kII3N8hFVzD--9iDttI_6pak6vHsCYRJFQnTgu3MQA=\" rel=\"nofollow\" target=\"_blank\">Tevogen Bio Holdings Inc.<\/a> (\u201cTevogen\u201d or the \u201cCompany) (Nasdaq: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mjBn_8TsaLmdLo1LJmSFNMdKsie9oqjbuHg_AtyXzRseJ7To_0jCoftvVzxLj4VyVS6Mkz8kB97Vt6L3m_49QmJpB6FYkmjAfRfSE4K3ulkjVA3kM-b2ppGx3nhmmlJd\" rel=\"nofollow\" target=\"_blank\">TVGN<\/a>), today announced it has received the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6FoYmJZRu82M-4qvJQmuarMmkVyDAX3zFMM2izxIJXwESEnEBPXYRR0Eb_72GfsxzRycyL0Ug29vrPF6mP-jdQOmBthHDiIfghsK9c65SMl0WHMp2L79X5maxzb5taSVUJtoOcN3Kswb8f1nRnfExXapvGca0n20PzyKvM1gt82mgf2B5oniA6MTbwCvbEXCiY4hw9UDjVg0T80CEyFMwg==\" rel=\"nofollow\" target=\"_blank\">previously reported<\/a> $1 million in funding to advance Tevogen.AI, its artificial intelligence\u2013powered drug discovery and development program.<\/p>\n<p>The funding is provided through an agreement with KRHP LLC, under which Tevogen received $2 million in January 2025 and may receive up to an additional $8 million, for an aggregate of $10 million in nondilutive funding. KRHP LLC is affiliated with an existing Tevogen investor. Following Tevogen.AI\u2019s <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YiV_Ogj-HP7KKl4zL06NaH_WTVK6OuTf57M24QMUYRQs8ZCyr23pSWAHaDZsPrmRYPKHci1Hgi13eyNGhDQrp-PDbFAxROD0_KdWxArYtxxBLOtw3PCsdL4xxBWUWH9k48Kv3afCPyNDV_qorGxNVIPWD2q4O4XCj_qsGgxV23YmNeC8Wpbd2h99lQZv7h4t-STA3qMAaKNgk6nzB7-gzrfNmPlQpnLWquMkkMV93c2zBXjP691B1C4rQho8ya2CEFaz_JEI4YZUuBdkwoIHiA==\" rel=\"nofollow\" target=\"_blank\">recent announcement<\/a> of the patent publication of its proprietary machine learning technology for predicting immunologically active peptides, a critical step in developing targeted therapies for cancers and infectious diseases, the Company plans to use the funding to accelerate Tevogen.AI\u2019s capabilities, enhancing target discovery, shortening development timelines, and improving treatment accessibility for large patient populations.<\/p>\n<p>Tevogen reinforces its operational efficiency and remains well\u2011capitalized. This funding and its existing agreement which provides access to a <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mVnlEn2SS7cxhSU6Ars0MGps8pIsCr34wvibrtmosJLCafahA15N_AadhNQoeMmRF7viB8TkGCfCPUR1LHnVGcc8p0dCdqbQF6AW7a3iBwt01hU1nmhrjpxxgW9l7jHYhI3kwFjkIsze_5ZDkWPXez1Z85ZjScj6qdATd8U303ZoMoj0z71ZwVuEFhB3aTZW\" rel=\"nofollow\" target=\"_blank\">$36 million line of credit<\/a>, ensures it has the resources needed to fully execute its current growth strategy.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p>This press release contains certain forward-looking statements, including without limitation statements relating to: the expected receipt of grant funding from KRHP LLC; Tevogen\u2019s plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen\u2019s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as \u201cmay,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cgoal,\u201d \u201copportunity,\u201d \u201cproject,\u201d \u201cbelieve,\u201d \u201cfuture,\u201d and similar words and expressions or their opposites. These statements are based on management\u2019s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company\u2019s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.<\/p>\n<p>Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen\u2019s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition and the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen\u2019s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen\u2019s limited operating history; and those factors discussed or incorporated by reference in Tevogen\u2019s Annual Report on Form 10-K.<\/p>\n<p>You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.<\/p>\n<p>\n        <strong>Contacts<\/strong>\n      <\/p>\n<p>Tevogen Bio Communications<\/p>\n<p>T: 1 877 TEVOGEN, Ext 701<\/p>\n<p>Communications@Tevogen.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNzg2MCM3MDg2NzY0IzIyODk5MTc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YTAwYjBkMzktODVmOC00ZGNkLThhNDItOWRjY2I0N2E0YjEwLTEzMDE0NjctMjAyNS0wOC0wNy1lbg==\/tiny\/Tevogen-Bio-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Funds will support advancement of Tevogen.AI, the Company\u2019s artificial intelligence\u2013driven drug discovery initiative. The $1 million is part of up to $10 million in previously announced non-dilutive grant funding from KRHP LLC. The Company remains well-capitalized, enabling it to fully execute its growth strategy. WARREN, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) &#8212; Tevogen Bio Holdings Inc. (\u201cTevogen\u201d or the \u201cCompany) (Nasdaq: TVGN), today announced it has received the previously reported $1 million in funding to advance Tevogen.AI, its artificial intelligence\u2013powered drug discovery and development program. The funding is provided through an agreement with KRHP LLC, under which Tevogen received $2 million in January 2025 and may receive up to an additional $8 million, for an aggregate of $10 million in &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-receives-1-million-to-accelerate-ai-driven-drug-discovery-remains-well-capitalized-to-execute-growth-strategy\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Tevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-872700","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Tevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-receives-1-million-to-accelerate-ai-driven-drug-discovery-remains-well-capitalized-to-execute-growth-strategy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Funds will support advancement of Tevogen.AI, the Company\u2019s artificial intelligence\u2013driven drug discovery initiative. The $1 million is part of up to $10 million in previously announced non-dilutive grant funding from KRHP LLC. The Company remains well-capitalized, enabling it to fully execute its growth strategy. WARREN, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) &#8212; Tevogen Bio Holdings Inc. (\u201cTevogen\u201d or the \u201cCompany) (Nasdaq: TVGN), today announced it has received the previously reported $1 million in funding to advance Tevogen.AI, its artificial intelligence\u2013powered drug discovery and development program. The funding is provided through an agreement with KRHP LLC, under which Tevogen received $2 million in January 2025 and may receive up to an additional $8 million, for an aggregate of $10 million in &hellip; Continue reading &quot;Tevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-receives-1-million-to-accelerate-ai-driven-drug-discovery-remains-well-capitalized-to-execute-growth-strategy\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-07T13:04:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNzg2MCM3MDg2NzY0IzIyODk5MTc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tevogen-receives-1-million-to-accelerate-ai-driven-drug-discovery-remains-well-capitalized-to-execute-growth-strategy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tevogen-receives-1-million-to-accelerate-ai-driven-drug-discovery-remains-well-capitalized-to-execute-growth-strategy\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Tevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy\",\"datePublished\":\"2025-08-07T13:04:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tevogen-receives-1-million-to-accelerate-ai-driven-drug-discovery-remains-well-capitalized-to-execute-growth-strategy\\\/\"},\"wordCount\":720,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tevogen-receives-1-million-to-accelerate-ai-driven-drug-discovery-remains-well-capitalized-to-execute-growth-strategy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUwNzg2MCM3MDg2NzY0IzIyODk5MTc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tevogen-receives-1-million-to-accelerate-ai-driven-drug-discovery-remains-well-capitalized-to-execute-growth-strategy\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tevogen-receives-1-million-to-accelerate-ai-driven-drug-discovery-remains-well-capitalized-to-execute-growth-strategy\\\/\",\"name\":\"Tevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tevogen-receives-1-million-to-accelerate-ai-driven-drug-discovery-remains-well-capitalized-to-execute-growth-strategy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tevogen-receives-1-million-to-accelerate-ai-driven-drug-discovery-remains-well-capitalized-to-execute-growth-strategy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUwNzg2MCM3MDg2NzY0IzIyODk5MTc=\",\"datePublished\":\"2025-08-07T13:04:31+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tevogen-receives-1-million-to-accelerate-ai-driven-drug-discovery-remains-well-capitalized-to-execute-growth-strategy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tevogen-receives-1-million-to-accelerate-ai-driven-drug-discovery-remains-well-capitalized-to-execute-growth-strategy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tevogen-receives-1-million-to-accelerate-ai-driven-drug-discovery-remains-well-capitalized-to-execute-growth-strategy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUwNzg2MCM3MDg2NzY0IzIyODk5MTc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUwNzg2MCM3MDg2NzY0IzIyODk5MTc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tevogen-receives-1-million-to-accelerate-ai-driven-drug-discovery-remains-well-capitalized-to-execute-growth-strategy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-receives-1-million-to-accelerate-ai-driven-drug-discovery-remains-well-capitalized-to-execute-growth-strategy\/","og_locale":"en_US","og_type":"article","og_title":"Tevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy - Market Newsdesk","og_description":"Funds will support advancement of Tevogen.AI, the Company\u2019s artificial intelligence\u2013driven drug discovery initiative. The $1 million is part of up to $10 million in previously announced non-dilutive grant funding from KRHP LLC. The Company remains well-capitalized, enabling it to fully execute its growth strategy. WARREN, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) &#8212; Tevogen Bio Holdings Inc. (\u201cTevogen\u201d or the \u201cCompany) (Nasdaq: TVGN), today announced it has received the previously reported $1 million in funding to advance Tevogen.AI, its artificial intelligence\u2013powered drug discovery and development program. The funding is provided through an agreement with KRHP LLC, under which Tevogen received $2 million in January 2025 and may receive up to an additional $8 million, for an aggregate of $10 million in &hellip; Continue reading \"Tevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-receives-1-million-to-accelerate-ai-driven-drug-discovery-remains-well-capitalized-to-execute-growth-strategy\/","og_site_name":"Market Newsdesk","article_published_time":"2025-08-07T13:04:31+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNzg2MCM3MDg2NzY0IzIyODk5MTc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-receives-1-million-to-accelerate-ai-driven-drug-discovery-remains-well-capitalized-to-execute-growth-strategy\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-receives-1-million-to-accelerate-ai-driven-drug-discovery-remains-well-capitalized-to-execute-growth-strategy\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Tevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy","datePublished":"2025-08-07T13:04:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-receives-1-million-to-accelerate-ai-driven-drug-discovery-remains-well-capitalized-to-execute-growth-strategy\/"},"wordCount":720,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-receives-1-million-to-accelerate-ai-driven-drug-discovery-remains-well-capitalized-to-execute-growth-strategy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNzg2MCM3MDg2NzY0IzIyODk5MTc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-receives-1-million-to-accelerate-ai-driven-drug-discovery-remains-well-capitalized-to-execute-growth-strategy\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-receives-1-million-to-accelerate-ai-driven-drug-discovery-remains-well-capitalized-to-execute-growth-strategy\/","name":"Tevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-receives-1-million-to-accelerate-ai-driven-drug-discovery-remains-well-capitalized-to-execute-growth-strategy\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-receives-1-million-to-accelerate-ai-driven-drug-discovery-remains-well-capitalized-to-execute-growth-strategy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNzg2MCM3MDg2NzY0IzIyODk5MTc=","datePublished":"2025-08-07T13:04:31+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-receives-1-million-to-accelerate-ai-driven-drug-discovery-remains-well-capitalized-to-execute-growth-strategy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-receives-1-million-to-accelerate-ai-driven-drug-discovery-remains-well-capitalized-to-execute-growth-strategy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-receives-1-million-to-accelerate-ai-driven-drug-discovery-remains-well-capitalized-to-execute-growth-strategy\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNzg2MCM3MDg2NzY0IzIyODk5MTc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUwNzg2MCM3MDg2NzY0IzIyODk5MTc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tevogen-receives-1-million-to-accelerate-ai-driven-drug-discovery-remains-well-capitalized-to-execute-growth-strategy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Tevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/872700","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=872700"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/872700\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=872700"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=872700"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=872700"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}